ectodomain
defin
dynam
conform
protein
structur
offer
snapshot
close
intermedi
open
apn
repres
distinct
function
state
coronaviru
envelop
protein
specif
recogn
open
apn
form
prevent
ectodomain
progress
close
form
substrat
hydrolysi
addit
drug
bind
activ
site
inhibit
coronaviru
bind
cell
surfac
apn
infect
drug
probabl
hinder
apn
transit
virusspecif
open
form
conclud
alloster
inhibit
apn
function
occur
ligand
suppress
ectodomain
motion
necessari
catalysi
viru
cell
entri
valid
lock
apn
disulfid
block
apn
dynam
thu
valuabl
approach
develop
drug
target
ectoenzym
aminopeptidas
wide
distribut
among
plant
anim
catalyz
amino
acid
cleavag
n
terminu
protein
peptid
numer
aminopeptidas
identifi
group
sever
famili
solubl
membranebound
bear
metal
ion
activ
site
also
known
metallopeptidas
metalloproteas
zinc
common
metal
ion
aminopeptidas
one
two
zinc
atom
present
activ
site
aminopeptidas
n
apn
belong
famili
zinc
metallopeptidas
also
term
gluzincin
compris
enzym
medic
interest
infecti
autoimmun
diseas
cancer
hypertens
apn
associ
variou
cell
function
diseas
term
moonlight
enzym
zincdepend
metallopeptidas
hydrolyz
n
terminu
biolog
peptid
extracellular
matrix
protein
apnmedi
peptid
hydrolysi
activ
import
regul
sever
physiolog
process
control
blood
pressur
angiotensin
cell
chemotaxi
addit
apn
link
cell
motil
tumor
metastasi
apn
overexpress
neovasculatur
includ
tumor
blood
vessel
relev
angiogenesi
discov
use
ngr
peptid
later
confirm
anim
model
peptid
inhibitor
target
apn
overexpress
tumor
prevent
tumor
cell
growth
invas
drug
bind
activ
site
protein
develop
treat
tumor
clinic
trial
addit
associ
angiogenesi
cancer
apn
major
coronaviru
cov
cell
entri
receptor
cov
recognit
apn
speciesspecif
specif
associ
nlink
glycosyl
apn
protein
defin
cov
recogn
apn
receptor
basi
virusreceptor
bind
specif
mammalian
apn
type
ii
membranebound
ectoenzym
dimer
cell
surfac
compos
short
cytoplasm
domain
follow
transmembran
domain
extracellular
ectodomain
amino
acid
residu
sever
nlink
olink
glycosyl
apn
ectodomain
compos
four
domain
domain
iv
connect
membran
short
linker
stalk
three
ntermin
domain
iiii
similar
homolog
domain
famili
member
wherea
domain
iv
diverg
domain
ii
thermolysinlik
fold
contain
zinccoordin
residu
conserv
activ
site
gluzincin
two
histidin
hexxh
motif
glutam
acid
residu
distal
motif
sever
crystal
structur
apn
complex
peptid
drug
show
substrat
bind
activ
site
provid
clue
peptid
hydrolysi
human
pig
apn
ectodomain
share
residu
ident
domain
architectur
dimer
ctermin
domain
iv
largest
apn
domain
accord
crystal
structur
mediat
protein
dimer
porcin
cov
recogn
membranedist
domain
iv
region
includ
nlink
glycan
pig
apn
well
small
caviti
form
domain
ii
iv
mode
cov
recogn
angiotensinconvert
enzym
dipeptidylpeptidas
distinct
apn
although
glycan
nlink
also
involv
interact
structur
metallopeptidas
tricorninteract
factor
endoplasm
reticulum
indic
famili
member
adopt
divers
conform
structur
defin
close
intermedi
open
state
base
access
catalyt
site
domain
ii
determin
posit
domain
iv
rel
domain
ii
propos
substrat
gain
access
activ
site
open
state
enzym
must
close
peptid
hydrolysi
nonetheless
role
catalysi
dynam
transit
state
determin
function
assay
use
monoclon
antibodi
mab
indic
dynam
conform
cell
surfac
apn
mab
recogn
subset
apn
molecul
presenc
epitop
cell
vari
substrat
andor
inhibitor
antibodi
bind
alter
protein
dimer
point
chang
apn
ectodomain
conform
cell
surfac
determin
sever
crystal
structur
dimer
human
porcin
apn
hapn
papn
ectodomain
reveal
dynam
conform
protein
dimer
preserv
structur
receptorbind
domain
rbd
porcin
cov
bound
specif
open
papn
form
inhibit
catalysi
probabl
prevent
apn
dynam
closur
contrast
drug
bound
activ
site
like
maintain
close
protein
inhibit
cov
protein
bind
infect
block
apn
ectodomain
motion
disulfid
bond
inhibit
function
thu
result
show
import
apn
dynam
catalysi
viru
infect
apn
ectodomain
structur
apn
protein
type
ii
membran
protein
ectodomain
express
requir
delet
ntermin
cytoplasm
transmembran
domain
introduct
secret
signal
sequenc
well
hemagglutinin
ha
tag
allow
protein
detect
purif
supplementari
fig
ntermin
middl
portion
hapn
papn
ectodomain
heavili
glycosyl
produc
cho
cell
see
method
purifi
protein
gener
distinct
crystal
form
differ
crystal
condit
tabl
method
past
report
papn
ectodomain
crystal
structur
complex
cov
spike
fragment
pdb
code
show
three
new
structur
apn
tabl
four
structur
ntermin
ha
tag
ectodomain
residu
disord
indic
larg
degre
flexibl
membran
proxim
polypeptid
ectodomain
hooklik
conform
form
domain
iv
contain
zinc
ion
activ
site
domain
ii
fig
expos
convex
side
domain
iv
mediat
similar
protein
dimer
distinct
crystal
approxim
monom
buri
dimer
interfac
tabl
indic
stabl
proteinprotein
interact
domain
iv
largest
apn
domain
diverg
aminopeptidas
famili
apn
domain
iv
seven
helixturnhelix
heat
repeat
singl
arm
repeat
form
three
alpha
helic
arm
repeat
variabl
domain
iv
region
hapn
papn
structur
contact
peptid
substrat
bound
activ
site
see
although
dimer
assembl
human
pig
apn
ectodomain
preserv
variou
crystal
conform
monom
differ
among
crystal
form
distanc
ntermin
region
ectodomain
form
dimer
vari
structur
tabl
supplementari
fig
crystal
captur
singl
apn
conform
monom
form
structur
identifi
three
distinct
apn
conform
base
activ
site
access
term
close
intermedi
open
form
fig
report
famili
member
observ
apn
structur
divers
indic
ectodomain
dynam
solut
cell
surfac
activ
site
access
domain
ii
differ
among
crystal
form
interdomain
adjust
apn
contact
domain
iv
domain
monom
vari
among
structur
wherea
domain
iviv
buri
surfac
monom
dimer
interfac
preserv
tabl
domain
iv
contact
domain
iii
chang
markedli
less
buri
surfac
domain
ii
domain
iiiv
interact
thu
mainli
stabil
close
apn
conform
notabl
differ
interdomain
contact
distinct
apn
form
tabl
domain
iii
distant
domain
iv
open
conform
apn
monom
fig
b
zinc
ion
catalyt
site
access
solvent
fig
domain
iii
modul
swing
toward
domain
iv
close
activ
site
fig
c
hapn
structur
adopt
intermedi
conform
crystal
fig
distanc
n
terminu
monom
dimer
angl
differ
fig
tabl
cell
surfac
domain
iii
modul
must
swing
domain
iv
fix
dimer
fig
supplementari
video
modul
movement
must
facilit
flexibl
polypeptid
link
domain
transmembran
domain
supplementari
fig
although
polypeptid
length
probabl
limit
interdomain
movement
shown
apn
less
pronounc
report
determin
tabl
type
interdomain
movement
also
differ
apn
domain
iiiiv
modul
move
togeth
rel
domain
iii
wherea
domain
iii
swing
domain
iv
apn
addit
hing
region
domain
iii
n
terminu
wherea
apn
domain
iv
n
terminu
domain
ii
iii
pivot
begin
first
third
domain
iv
helix
perpendicular
swing
angl
fig
differ
apn
motion
compar
aminopeptidas
probabl
relat
dimer
format
observ
famili
member
domain
ii
buri
surfac
increas
due
interact
domain
iv
conform
chang
open
close
tabl
thu
reduc
access
activ
site
caviti
fig
aminopeptidas
dynam
thought
necessari
catalysi
close
met
residu
papneh
replac
selenomet
see
method
highestresolut
shell
parenthes
favor
allow
outlier
residu
ramachandran
plot
well
number
ectodomain
asymmetr
unit
asu
shown
statist
papnrbd
crystal
structur
discuss
report
earlier
pdb
code
structur
represent
supplementari
fig
fig
close
papn
side
chain
phenylalanin
domain
iv
place
hydrolyz
peptid
bond
whose
carbonyl
group
coordin
zinc
ion
phenylalanin
locat
loop
connect
singl
domain
iv
arm
repeat
human
pig
apn
fig
penetr
activ
site
groov
close
conform
lock
peptid
readi
hydrolysi
domain
iv
residu
preced
loop
contact
domain
ii
close
papn
similar
loop
conform
seen
close
hapn
structur
pdb
code
phenylalanin
side
chain
close
apn
probabl
hinder
peptid
releas
transloc
process
hydrolysi
like
bind
residu
zinc
ion
requir
remov
phenylalanin
plug
domain
ii
displac
away
domain
iv
phenylalanin
adopt
distinct
conform
intermedi
open
apn
conform
fig
domain
ii
movement
accompani
conform
chang
loop
domain
iv
supplementari
video
becam
solventexpos
phenylalanin
side
chain
face
domain
iv
intermedi
open
conform
peptid
plug
remov
activ
site
chang
would
facilit
releas
ntermin
residu
hydrolysi
small
interdomain
movement
intermedi
apn
structur
would
suffici
peptid
process
fig
previous
describ
detail
cov
spike
rbdpapn
bind
interfac
porcin
cov
spike
rbd
bind
papn
region
distant
catalyt
site
supplementari
fig
critic
cov
receptorbind
motif
bear
expos
tryptophan
penetr
narrow
caviti
form
domain
ii
iv
fig
tryptophan
aromat
side
chain
stack
onto
papn
domain
iv
residu
trap
domain
iv
residu
one
side
domain
ii
residu
fig
main
chain
domain
ii
residu
close
contact
tryptophan
side
chain
imino
nitrogen
form
hydrogen
bond
domain
iv
main
chain
carbonyl
domain
ivbas
superposit
open
papn
bound
rbd
close
papn
show
shift
domain
ii
main
chain
region
contact
rbd
region
collid
cov
tryptophan
fig
close
ectodomain
would
hinder
penetr
viral
tryptophan
papn
domain
ii
iv
cov
bind
apn
would
lock
protein
open
conform
fig
prevent
ectodomain
movement
probabl
necessari
peptid
hydrolysi
fig
analyz
catalyt
activ
solubl
human
pig
apn
ectodomain
presenc
porcin
cov
fragment
bear
rbd
fig
solubl
protein
specif
inhibit
papnmedi
catalysi
measur
hydrolysi
lpna
substrat
effect
hapn
activ
tgev
transmiss
gastroenter
coronaviru
spike
bind
hapn
lack
nlink
glycan
recogn
porcin
cov
papn
isol
rbd
suffici
inhibit
papn
catalysi
fig
inhibit
depend
rbd
concentr
high
rbd
papn
ratio
need
achiev
maximum
inhibit
fig
decreas
slowli
min
fig
drug
bind
catalyt
site
inhibit
cov
bind
apn
nonhydrolyz
drug
bind
apn
catalyt
site
inhibit
catalysi
prevent
angiogenesi
tumor
growth
appear
restrict
ectodomain
conform
chang
shown
reduct
number
apn
conformationspecif
fig
residu
contact
rbd
stick
carbon
yellow
domain
ii
green
domain
iv
residu
shown
superpos
close
structur
carbon
grey
rbd
motif
penetr
papn
caviti
shown
grey
surfac
residu
stick
carbon
cyan
magenta
trp
scientif
report
doi
mab
epitop
cell
surfac
activ
site
epitop
recogn
mab
decreas
presenc
actinonin
indic
apn
closur
crystal
structur
aminopeptidas
complex
drug
show
preferenti
adopt
close
state
drug
bind
would
thu
compet
substrat
activ
site
bind
might
also
restrict
aminopeptidas
dynam
need
peptid
process
structur
papnrbd
complex
indic
porcin
cov
would
specif
open
conform
fig
restrict
apn
ectodomain
open
activ
sitebind
drug
would
thu
alloster
effect
cov
bind
test
hypothesi
studi
tgev
rbd
bind
cell
surfac
papn
presenc
drug
bind
activ
site
fig
flow
cytometri
determin
bind
rbdfc
fusion
protein
cell
express
papn
activ
site
mutant
papnhhaa
alon
variou
drug
fig
b
analyz
effect
natur
apn
inhibitor
actinonin
bestatin
reduc
rbdfc
bind
cell
surfac
papn
fig
left
evalu
four
synthet
aminobenzosuberon
ab
deriv
bind
high
affin
select
apn
supplementari
fig
four
ab
molecul
prevent
rbd
bind
papn
effect
increas
apnbind
affin
fig
left
bulkier
compound
contain
phenyl
group
bind
highest
affin
apn
effici
block
bind
tgev
rbd
papn
cell
surfac
inhibitori
molecul
bind
apn
activ
site
distant
apn
region
recogn
cov
supplementari
fig
determin
whether
inhibitori
effect
link
drug
bind
papn
activ
site
analyz
rbd
bind
papnhhaa
mutant
lack
two
histidin
coordin
zinc
ion
supplementari
fig
stain
rbdfc
protein
similar
cell
express
mutant
alon
drug
fig
right
b
right
show
compound
bind
papn
activ
site
necessari
prevent
rbd
bind
distant
site
addit
inhibit
rbd
bind
papn
drug
concentrationdepend
fig
amount
compound
need
reach
inhibit
ic
decreas
compound
affin
apn
bestatin
ki
actinonin
ki
ki
nm
result
show
drug
bind
cov
cell
entri
infect
nonetheless
found
activ
sitebind
molecul
hinder
cov
protein
bind
might
inhibit
viru
infect
studi
low
affin
bind
drug
bestatin
show
reduct
tgev
infect
viru
particl
high
receptorbind
avid
drug
might
suffici
affin
maintain
apn
molecul
close
select
compound
high
affin
apn
concentr
inhibit
capillari
tube
format
cell
cultur
cytotox
cultur
observ
toxic
ab
concentr
shown
therefor
analyz
tgevmedi
cytopath
effect
four
ab
molecul
actinonin
concentr
monitor
inhibit
viru
infect
log
log
fig
concentr
loweraffin
compound
actinonin
inhibit
bromo
substitu
predict
interact
phenylalanin
plug
substrat
close
conform
interact
like
help
maintain
close
ectodomain
effici
prevent
viru
bind
tgev
repres
extens
studi
anim
cov
use
papn
cell
entri
determin
whether
inhibit
viru
infect
link
cell
entri
analyz
tgev
replic
h
postinfect
found
viru
entri
decreas
concentr
fig
addit
viru
absorpt
inhibit
viru
growth
shown
indic
prevent
viru
bind
cell
addit
studi
effect
concentr
tgev
cell
infect
observ
tgev
cytopath
effect
reduc
cell
surviv
increas
higher
concentr
fig
ab
compound
select
apn
molecul
design
inhibit
apn
catalyt
activ
tumor
growth
show
also
prevent
cov
cell
infect
analyz
import
apn
dynam
engin
disulfid
bond
bridg
domain
ii
iv
restrict
ectodomain
motion
replac
papn
domain
ii
domain
iv
andor
cystein
lock
ectodomain
close
form
interdomain
disulfid
bridg
main
chain
respect
close
form
move
away
open
form
supplementari
fig
disulfid
bond
format
papn
thu
prevent
ectodomain
motion
express
papncystein
mutant
cell
surfac
compar
catalyt
cov
bind
activ
wild
type
papn
fig
papn
cystein
mutant
show
reduc
catalyt
activ
fig
tgev
rbd
bind
fig
rel
wild
type
protein
transfect
express
similar
protein
amount
higher
activ
papn
mutant
suggest
disulfid
bond
labil
bond
probabl
flexibl
loop
supplementari
fig
treatment
reduc
agent
restor
catalysi
rbd
bind
cystein
mutant
affect
wild
type
papn
bind
activ
fig
reduc
disulfid
bond
fulli
restor
rbd
bind
catalysi
partial
recov
papn
mutant
substrat
hydrolysi
propos
close
ectodomain
see
would
facilit
rebuild
disulfid
lock
close
form
phenylalanin
domain
iv
arm
repeat
insid
activ
site
probabl
imped
substrat
process
fig
papn
cystein
mutant
bound
markedli
less
rbd
wild
type
protein
confirm
cov
protein
bind
close
papn
steric
hinder
fig
cov
recogn
open
form
overal
result
valid
function
relev
apn
ectodomain
conform
motion
structur
dynam
intrins
properti
aminopeptidas
apn
crystal
structur
report
indic
dynam
conform
ectodomain
function
studi
show
relev
catalysi
viru
infect
distinct
ectodomain
region
mediat
function
agent
bind
one
region
prevent
activ
link
alloster
effect
ligand
probabl
caus
restrict
apn
conform
dynam
confirm
disulfid
bond
mutant
demonstr
prevent
ectodomain
motion
lock
apn
form
inhibit
function
apn
ectodomain
movement
less
pronounc
differ
report
aminopeptidas
differ
could
due
apn
dimer
conform
linkag
cell
surfac
dimer
engag
domain
iv
region
found
dimer
conserv
apn
structur
close
intermedi
open
apn
domain
iv
thu
move
describ
protein
form
dimer
fix
conform
apn
dimer
determin
domain
iii
modul
swing
domain
iv
supplementari
video
hing
domain
iv
ntermin
region
length
movement
less
mark
apn
although
two
protein
similar
close
conform
displac
apn
domain
ii
iii
must
limit
length
flexibl
polypeptid
link
domain
transmembran
region
whose
movement
restrict
membran
fluiditi
extent
apn
movement
nonetheless
appear
suffici
releas
hydrolyz
peptid
ntermin
residu
plug
domain
iv
open
intermedi
apn
conform
fig
clear
monom
dimer
move
whether
movement
random
synchron
invers
direct
experi
hapn
antibodi
shown
tgev
rbd
fig
suggest
molecul
adopt
differ
form
data
impli
apn
monom
maintain
distinct
conform
supplementari
video
crystal
structur
report
provid
snapshot
apn
dynam
conform
also
guid
experi
demonstr
role
viru
entri
cell
catalysi
switch
proteolyt
activ
close
inact
open
conform
propos
sever
aminopeptidas
dynam
thought
import
peptid
hydrolysi
releas
aminopeptidas
activ
site
region
join
domain
iv
arm
repeat
penetr
activ
site
groov
close
pig
human
apn
structur
report
elsewher
fig
conserv
phenylalanin
region
lock
substrat
coordin
zinc
ion
permit
hydrolysi
peptid
process
like
requir
remov
phenylalanin
lock
open
apn
ectodomain
facilit
ntermin
residu
releas
peptid
transloc
steric
hinder
close
conform
fig
inher
flexibl
domain
iv
arm
repeat
demonstr
link
interdomain
arrang
might
also
enabl
substrat
process
indic
ectodomain
movement
particip
peptid
hydrolysi
local
chang
conserv
tyrosin
papn
activ
site
aminopeptidas
also
suggest
import
among
apn
form
absenc
conform
switch
activ
site
residu
domain
ii
supplementari
fig
nonetheless
indic
tyrosin
movement
link
interdomain
motion
disulfid
bond
lock
apn
close
conform
drug
prevent
open
ectodomain
inhibit
cov
protein
bind
cell
infect
wherea
porcin
cov
protein
probabl
hinder
apn
transit
close
form
peptid
hydrolysi
result
verifi
critic
role
apn
dynam
cov
infect
catalysi
demonstr
open
apn
structur
inact
peptid
hydrolysi
antiapn
antibodi
inhibit
apn
activ
reduc
tumor
growth
like
block
ectodomain
movement
alloster
inhibit
apn
function
shown
use
viral
protein
drug
like
due
suppress
apn
transient
conform
state
shown
enzym
block
apn
movement
prevent
function
suggest
new
approach
develop
drug
target
protein
small
molecul
conformationspecif
antibodi
inhibitor
ectodomain
motion
bind
activ
site
interact
distant
site
shown
cov
spike
fragment
high
affin
drug
design
inhibit
catalysi
tumor
growth
prevent
cov
infect
indic
target
apn
ectodomain
dynam
valuabl
approach
block
apn
function
relat
cancer
progress
viru
infect
catalysi
determin
min
absorb
nm
see
fig
method
rel
rbdfc
bind
transfect
cell
determin
mean
fluoresc
intens
comput
flow
cytometri
fig
domain
ii
iv
residu
replac
cystein
indic
bottom
see
supplementari
fig
mean
sd
n
papn
protein
met
residu
replac
selenomet
semet
papn
produc
use
methionineand
glutaminefre
dmem
invitrogen
supplement
dialyz
fetal
calf
serum
fc
lselenomethionin
sigma
apn
protein
secret
cultur
supernat
purifi
affin
chromatographi
antiha
mab
roch
follow
size
exclus
chromatographi
hepessalin
buffer
mm
hepe
mm
nacl
ph
prepar
solubl
cov
protein
use
describ
protein
deriv
porcin
cov
glycoprotein
bear
papnbind
domain
solubl
tgev
rbd
deriv
glycoprotein
tgev
strain
genbank
acc
contain
residu
ntermin
ha
peptid
flag
sequenc
monoval
rbd
variant
human
fc
bival
rbdfc
variant
ctermin
end
cov
protein
produc
cholec
cell
purifi
describ
analysi
apn
catalysi
apn
catalyt
activ
determin
use
leucin
pnitroanilid
lpna
sigma
standard
spectrophotometr
assay
plate
solubl
protein
transfect
cell
studi
cov
protein
inhibit
apn
catalysi
solubl
apn
ectodomain
gml
nm
ad
duplic
well
alon
solubl
cov
protein
variant
follow
lpna
substrat
mm
l
final
volum
plate
incub
room
temperatur
od
nm
measur
differ
time
background
od
well
without
apn
subtract
determin
specif
catalyt
activ
similar
procedur
use
cell
express
papn
hr
transfect
od
well
mocktransfect
cell
taken
background
cell
sampl
express
variou
amount
papn
membran
use
normal
activ
papn
cystein
mutant
rel
activ
mutant
wild
type
determin
ratio
papn
mutant
wild
type
od
sampl
protein
express
monitor
flow
cytometri
see
cov
protein
bind
apn
stabli
transfect
chopapn
chopapn
mutant
cell
transient
transfect
cell
use
papn
contain
ha
peptid
c
terminu
monitor
cell
surfac
express
cho
cell
papnhhaa
mutant
two
activ
site
histidin
replac
alanin
wherea
papn
cystein
mutant
domain
ii
domain
iv
andor
substitut
cystein
analyz
effect
rbd
bind
papn
two
natur
inhibitor
apn
enzym
activ
bestatin
actinonin
sigma
well
four
synthet
ab
compound
bestatin
actinonin
dissolv
mm
pb
wherea
ab
compound
use
mm
dmso
wild
type
mutant
papnexpress
cell
use
flow
cytometri
monitor
tgev
rbd
bind
cell
surfac
papn
essenti
report
cell
wash
three
time
cold
pb
resuspend
cellsml
pb
supplement
heatinactiv
fc
bovin
serum
albumin
bsa
bind
buffer
l
cell
suspens
ad
plate
nunc
cell
sediment
resuspend
l
gml
rbdfc
solut
alon
inhibitor
indic
concentr
min
unrel
fc
fusion
protein
use
control
cell
wash
incub
antihuman
igg
fluorescein
isothiocyan
fitc
label
secondari
antibodi
min
mean
fluoresc
intens
determin
beckman
coulter
epic
background
cell
stain
fc
protein
subtract
determin
specif
rbdfc
bind
cell
surfac
papn
parallel
amount
cell
surfac
papn
express
determin
flow
cytometri
antiha
mab
roch
antimous
fitclabel
secondari
antibodi
invitrogen
analysi
papn
cystein
mutant
bind
activ
normal
cell
surfac
protein
amount
explain
catalyt
activ
qrtpcr
quantit
revers
transcript
polymeras
chain
reaction
stabl
transfect
cell
cellswel
dmem
dulbecco
modifi
eagl
medium
fc
plate
plate
h
plate
transfer
medium
remov
l
bind
buffer
alon
apnbind
drug
rdb
protein
ad
well
min
solut
replac
l
viru
inoculum
multipl
infect
moi
alon
inhibitor
bind
buffer
viru
adsorpt
cell
wash
three
time
bind
buffer
incub
dmem
fc
h
co
cell
detach
lyse
l
tri
reagent
sigma
rna
extract
cdna
gener
g
rna
use
high
capac
cdna
revers
transcript
kit
appli
biosystem
realtim
pcr
reaction
l
perform
triplic
use
l
cdna
sampl
l
hot
firepol
evagreen
qpcr
mix
plu
rox
soli
biodyn
l
specif
primer
mous
actin
tgev
gene
real
time
pcr
system
appli
biosystem
use
standard
protocol
data
analyz
softwar
use
compar
ct
method
ct
tgev
express
rel
actin
determin
ratio
valu
alon
inhibitor
use
rel
cell
entri
infect
cytopath
effect
tgev
inhibit
porcin
st
cell
one
day
seed
cellswel
plate
cell
transfer
preincub
l
bind
buffer
alon
inhibitor
duplic
solut
replac
l
serial
dilut
viru
inoculum
inhibitor
dmso
control
incub
h
cell
wash
three
time
dmem
fc
incub
alon
inhibitor
two
day
determin
cell
surviv
infect
medium
remov
cell
formalinfix
stain
crystal
violet
viabil
determin
optic
densiti
od
nm
ratio
well
without
viru
determin
calcul
cell
surviv
see
supplementari
fig
crystal
diffract
data
collect
endoglycosidas
htreat
h
papn
papneh
ectodomain
crystal
sit
drop
techniqu
crystal
solut
polyethylen
glycol
peg
ph
mgml
protein
sampl
altern
nativ
glycosyl
papn
ectodomain
crystal
prepar
crystal
solut
mm
sodium
acet
ph
hapn
ectodomain
mgml
crystal
solut
mm
imidazolehcl
ph
crystal
frozen
crystal
solut
contain
ethylen
glycol
diffract
data
collect
european
synchrotron
radiat
facil
esrf
swiss
light
sourc
sl
pxii
beamlin
diffract
data
process
xd
scale
scala
program
statist
data
see
tabl
structur
determin
structur
semet
papneh
protein
solv
combin
molecular
replac
mr
singlewavelength
anomal
dispers
sad
method
crystal
contain
two
molecul
asymmetr
unit
tabl
partial
structur
obtain
mr
use
phaser
program
domain
iii
tricorninteract
factor
pdb
code
share
residu
ident
papn
phaser
llg
valu
best
mr
solut
wherea
rfz
valu
tfz
valu
use
mrsad
protocol
autorickshaw
server
determin
complet
papneh
structur
start
partial
mr
structur
use
semet
papneh
crystal
diffract
data
collect
selenium
peak
wavelength
final
structur
includ
two
papn
molecul
asymmetr
unit
adjust
manual
refin
phenixrefin
use
data
extend
resolut
statist
see
tabl
papneh
structur
compris
residu
zinc
atom
coordin
enzym
activ
site
apn
ectodomain
structur
tabl
determin
mr
method
use
papneh
structur
search
model
two
ensembl
includ
domain
ii
iii
isol
domain
iv
use
mr
structur
determin
phaser
structur
refin
phenixrefin
statist
tabl
structur
engin
tag
residu
ntermin
ectodomain
disord
includ
final
model
electron
densiti
map
activ
site
residu
nlink
glycan
shown
supplementari
fig
respect
structur
represent
prepar
pymol
pymolorg
